HRTX News and Press, Heron Therapeutics Inc. From 10/20/22

Summary Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that Pacira is working to address and growth should resume in the following qua...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks have always fascinated investors. That’s because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers. While it’s never a good idea to go overweight on penny stocks, invest...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can ...

Summary Heron addressed a key problem recently - its cash balance and cash burn. The cash raised and cost reductions have significantly extended the cash runway. However, much better growth of Zynrelef is required for the stock to recover in a more meaningful way. Aponvie'...

Commercial-stage biotech Heron Therapeutics, Inc. ( NASDAQ: HRTX ) announced Friday that the FDA approved its intravenous injection Aponvie (aprepitant) for the prevention of postoperative nausea and vomiting (PONV) in adults. HRTX shares are currently on hold for trading. ...

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) PR Newswire - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK 1 ) receptor antagoni...

Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere. And bad news can bring their share prices crashing down. Our Foolish trio is optimistic about Mirati Therapeutics (NASDAQ: MRTX) , Novavax (NASDAQ: NVAX) and Heron Therapeu...

Since the mid-June lows, highly shorted names have again been outperforming. On a relative basis, the most heavily shorted stocks have been outperforming the Russell 3,000 in that time. This has resulted in the relative strength line to break out of the downtrend that has been in ...

Heron Therapeutics, Inc. (HRTX) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chief Executive Officer and Chairman John Poyhonen ...